Molecular PROfiling in Early Clinical Trials- North East (PROSPECT-NE)
Research type
Research Study
Full title
Molecular PROfiling in Early Clinical Trials- North East (PROSPECT-NE)
IRAS ID
216629
Contact name
Alastair Greystoke
Contact email
Sponsor organisation
Newcastle upon Tyne Hospitals NHS Foundation Trust
Duration of Study in the UK
3 years, 11 months, 31 days
Research summary
The development of new drugs for patients with cancer is increasingly aimed at targeting the genetic abnormalities that have arisen within the tumour. Patients who have exhausted all standard treatment options for their cancer may be referred to the Sir Bobby Robson Early Clinical Trials Unit (SBRU) for consideration of early clinical trials, investigating the safe dose, side effect profile and effectiveness of new anti-cancer drugs The tumour molecular abnormalities present in patients presenting for consideration of early clinical trials in the North East of England is not known. We would like to know this information to help prioritise which drugs should b e investigated in Newcastle. This study will assess the molecular profile of the tumours of patients referred to SBRU on left over samples from the biopsy or surgery where their cancer was diagnosed.
Unfortunately patients may wait several months whilst awaiting a slot on a suitable early clinical trial. Some of these patients may become less well to the point where they are not able to safely enrol on an early clinical trial ,or stay on treatment long enough to see if it will work. We want to see if we can in the future use blood tests that estimate the amount of cancer a patient has, and the impact on their body to better monitor patients whilst they are waiting for clinical trials.REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
17/NE/0208
Date of REC Opinion
26 Jul 2017
REC opinion
Further Information Favourable Opinion